|Appearance:||A crystalline solid|
Clindamycin inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.
Clindamycin is a semisynthetic analogue of lincomycin. Clindamycin primarily inhibits the initiation of peptide chain synthesis by deregulating enzyme-catalyzed initiation of peptide bounds. Clindamycin appears to have a modest effect on protein synthesis by certain mammalian cells.
Clindamycin (50mg/kg daily administrated by intramuscular) increases the survival rate of monkeys infected with penicillin-resistant S. aureu to 87.5% (7/8).